Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'Maison F, Grammond P, Barnett M, Lechner-Scott J, Alroughani R, Trojano M, Lugaresi A, Granella F, Pucci E, Vucic S; MSBase Study Group. Spelman T, et al. Among authors: pucci e. Eur J Neurol. 2016 Apr;23(4):729-36. doi: 10.1111/ene.12929. Epub 2016 Jan 19. Eur J Neurol. 2016. PMID: 26782663
BREMSO: a simple score to predict early the natural course of multiple sclerosis.
Bergamaschi R, Montomoli C, Mallucci G, Lugaresi A, Izquierdo G, Grand'Maison F, Duquette P, Shaygannejad V, Alroughani R, Grammond P, Boz C, Iuliano G, Zwanikken C, Petersen T, Lechner-Scott J, Hupperts R, Butzkueven H, Pucci E, Oreja-Guevara C, Cristiano E, Pia Amato MP, Havrdova E, Fernandez-Bolanos R, Spelman T, Trojano M. Bergamaschi R, et al. Among authors: pucci e. Eur J Neurol. 2015 Jun;22(6):981-9. doi: 10.1111/ene.12696. Epub 2015 Mar 25. Eur J Neurol. 2015. PMID: 25808578
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group. Lorscheider J, et al. Among authors: pucci e. Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2. Eur J Neurol. 2019. PMID: 30298572 Free article.
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand'Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H; MSBase Investigators. Spelman T, et al. Among authors: pucci e. Pharmacoeconomics. 2022 Mar;40(3):323-339. doi: 10.1007/s40273-021-01106-6. Epub 2021 Dec 18. Pharmacoeconomics. 2022. PMID: 34921350 Free PMC article.
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care.
Solari A, Martinelli V, Trojano M, Lugaresi A, Granella F, Giordano A, Messmer Uccelli M, D'Alessandro R, Pucci E, Confalonieri P, Borreani C; SIMS-Trial group. Solari A, et al. Among authors: pucci e. Mult Scler. 2010 Nov;16(11):1393-405. doi: 10.1177/1352458510380417. Epub 2010 Sep 21. Mult Scler. 2010. PMID: 20858692 Clinical Trial.
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E; CoSa Study Group. Lugaresi A, et al. Among authors: pucci e. Clin Neuropharmacol. 2008 May-Jun;31(3):167-72. doi: 10.1097/wnf.0b013e3181571a8e. Clin Neuropharmacol. 2008. PMID: 18520983
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, Gasperini C, Florio C, Pucci E, Maddestra M, Spitaleri D, Lus G, Ardito B, Farina D, Rossi M, Di Carmine C, Altobelli E, Maccarone B, Casalena A, De Luca G, Travaglini D, Di Ioia M, Di Tommaso V, Fantozzi R, Ruggieri S, Provinciali L, De Riso S, Mundi C, Fuiani A, Galgani S, Ruggieri S, Maniscalco GT, Giuliani G, Cartechini E, Petretta V, Fratta M, Alfieri G, Gatto M, Carolei A; Natalizumab Long-Term Treatment Study group. Totaro R, et al. Among authors: pucci e. Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):147-54. doi: 10.1177/039463201402700201. Int J Immunopathol Pharmacol. 2014. PMID: 25004826 Free article.
Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial.
Borreani C, Giordano A, Falautano M, Lugaresi A, Martinelli V, Granella F, Tortorella C, Plasmati I, Radaelli M, Farina D, Dalla Bella E, Bianchi E, Acquarone N, Miccinesi G, Solari A; SIMS-Trial group. Borreani C, et al. Health Expect. 2014 Feb;17(1):36-48. doi: 10.1111/j.1369-7625.2011.00736.x. Epub 2011 Nov 1. Health Expect. 2014. PMID: 22040528 Free PMC article.
252 results